TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00394563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 25 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 50 mcg/kg
Study: NCT04304885

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonication method
Description: Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
Study: NCT04132635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial dermis
Description: artificial dermis will be used after fully debridement of the wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial dermis
Description: artificial dermis will be used after fully debridement of the wound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: growth factor
Description: growth factor
Study: NCT00539617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tarceva single agent therapy: 150 mg/day PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 IV once every 2 weeks for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV once every 2 weeks for 16 weeks
Study: NCT02410824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A toric lens
Description: toric contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A toric lens
Description: toric contact lens
Study: NCT02084238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
Study: NCT03146780

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional impression
Description: A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Scan 1
Description: Direct intra-oral digital scans using Sirona Omnicam software.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Scan 2
Description: Direct intra-oral digital scans using Planmeca Planscan software.
Study: NCT00394563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 100 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 200 mcg/kg
Study: NCT03775252

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
Study: NCT03068312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: IVA 150 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: IVA 150 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA tablet.
Study: NCT01852045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the detrusor wall on Day 1.
Study: NCT03146780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Scan 3
Description: Direct intra-oral digital scans using 3M True Definition software.
Study: NCT03974412

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head Up Tilt Table (HUT)
Description: Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder
Description: ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
Study: NCT01828138

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sodium
Description: supplemental sodium tablets 150-200 mmol/day in 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sodium
Description: supplemental sodium tablets 150-200 mmol/day in 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sodium
Description: supplemental sodium tablets 150-200 mmol/day in 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo are given in 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo are given in 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo are given in 5 days
Study: NCT00394563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00693004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-03140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Study: NCT00536458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: mini chep+ radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MINI CHEP
Description: chemotherapy minichep 6 courses
Study: NCT01521260

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
Study: NCT00693004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04103463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive stepping exercise
Description: An exercise intervention based on the principle of square stepping exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Home exercise
Study: NCT04668924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epi-on PiXL in high oxygen
Description: After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for \< 45 Diopters (D) 7.2J/cm\^2 will be used; for 45-50D 10J/cm\^2 will be used; for \> 50D 15 J/cm\^2 will be used.
Study: NCT01853072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic Suspension, 0.3%
Description: Test intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac vehicle
Description: Inactive ingredients used as placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone acetate
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Study: NCT02544334

Intervention type: PROCEDURE
Intervention: Dental Plaque
Description: All participants will have dental plaque removed from different tooth surfaces for supragingival.

Intervention type: PROCEDURE
Intervention: Dental Plaque
Description: All participants will have dental plaque removed from different tooth surfaces for supragingival.

Intervention type: PROCEDURE
Intervention: Dental Plaque
Description: All participants will have dental plaque removed from different tooth surfaces for supragingival.

Intervention type: PROCEDURE
Intervention: Dental Plaque
Description: All participants will have dental plaque removed from different tooth surfaces for supragingival.

Intervention type: OTHER
Intervention: Multi-dimensional health assessment questionnaire (MDHAQ)
Description: The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.

Intervention type: OTHER
Intervention: Multi-dimensional health assessment questionnaire (MDHAQ)
Description: The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
Study: NCT01521260

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
Study: NCT03245827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: clomiphene capsule 25mg twice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule 25mg twice a week
Study: NCT02544334

Intervention type: OTHER
Intervention: Multi-dimensional health assessment questionnaire (MDHAQ)
Description: The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
Study: NCT01852045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the detrusor wall on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the detrusor wall on Day 1.
Study: NCT02544334

Intervention type: OTHER
Intervention: Saliva Collection
Description: All participants will have a saliva collection.

Intervention type: OTHER
Intervention: Saliva Collection
Description: All participants will have a saliva collection.

Intervention type: OTHER
Intervention: Saliva Collection
Description: All participants will have a saliva collection.

Intervention type: OTHER
Intervention: Saliva Collection
Description: All participants will have a saliva collection.
Study: NCT02971020

Intervention type: OTHER
Group type: OTHER
Intervention: Observational/Cognitive Assessment
Description: Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).

Intervention type: OTHER
Group type: OTHER
Intervention: Observational/Cognitive Assessment
Description: Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
Study: NCT01284361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 cm Intermittent Catheter
Description: Randomized cross-over

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 40 cm Intermittent Catheter
Description: randomized cross-over
Study: NCT06522217

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasoalveolar molding appliance
Description: making impression then make the conventional lab procedures for group A for the production of conventional appliances

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: digital nasoalveolar molding appliance
Description: group B scanning the model and designing the appliances on 3shap and 3d printing the appliances
Study: NCT01528007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone pharmacotherapy
Description: Naltrexone 50mg when graving to gamble.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill with no active ingredients.
Study: NCT01527383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to V212 vaccine
Study: NCT00746733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Description: 50mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall XR (mixed salts amphetamine)
Description: 20mg capsule
Study: NCT01497808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT03358641

Intervention type: OTHER
Intervention: level of physical activity
Description: According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
Study: NCT00849875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2132231A
Description: Intramuscular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Intravenous administration Chemotherapy
Study: NCT02089152

Intervention type: OTHER
Group type: OTHER
Intervention: An educational programme for prevention of melioidosis
Description: The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
Study: NCT01497808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study: NCT04686617

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Vibration
Description: Oral B HummingBird device (Procter\&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
Study: NCT02827201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI.3
Description: For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel+ gemcitabine
Description: For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel+ gemcitabine
Description: For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
Study: NCT03111771

Intervention type: PROCEDURE
Intervention: carcinological surgery
Description: carcinological surgery for Group K +
Study: NCT05794594

Intervention type: DEVICE
Intervention: 3D printed personalized extendable prosthesis
Description: 3D printed personalized extendable prosthesis replacement for limb preservation in children
Study: NCT03918005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic load diet
Description: Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Description: Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
Study: NCT02773862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study: NCT03894384

Intervention type: DIAGNOSTIC_TEST
Intervention: Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)
Description: Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)
Description: Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
Study: NCT02745717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood
Description: transfusion of one unit of at least 4/6 HLA loci matched cord blood.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Oral Product
Description: administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Oral Product
Description: administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
Study: NCT00657150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 220 mg once daily
Study: NCT05226091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
Study: NCT02973191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCAR015
Study: NCT02805231

Intervention type: OTHER
Intervention: Vitamin D receptor polymorphic analysis

Intervention type: OTHER
Intervention: Vitamin D receptor polymorphic analysis
Study: NCT02416700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant surgery
Description: Surgery of dental implants in one side of the mouth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant surgery (Straumann®)
Description: Dental implant surgery in one of the sides of the mouth
Study: NCT02192229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50.000 IU vitamin D3 (Biodal 50,000 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (to mimic Biodal 50,000 IU)
Description: Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
Study: NCT01046227

Intervention type: BIOLOGICAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
Description: Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
Study: NCT04411537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: During neo-CRT: 625mg/m2 bid Monday-Friday per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiotherapy
Description: IMRT DT: 50Gy/25Fx
Study: NCT00012363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
Study: NCT01697150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiAs Diabetes Assistant Wearable Artificial Pancreas Platform
Description: Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
Study: NCT02726191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial Match Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temporal Sequence Reconstruction Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Token Task Exercise
Study: NCT02223949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook double balloon catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE1 tablet
Study: NCT02404038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nur-Isterate
Description: Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).